NCT05817188Completed
Medication Repurposing to Stop Cognitive Decline in Dementia
Translational Identification of Medication Repurposing Candidates to Slow Cognitive Decline in Dementia
Source: ClinicalTrials.gov · Last updated 2 May 2025
Brief summary (registry, in English)
Dementia creates a great personal and societal burden and there are currently no treatments to stop memory loss. Many patients with dementia take medications to treat other conditions, e.g. high blood pressure and cholesterol. Some of these medications may have central effects on the pathophysiological processes leading to dementia. Medication repurposing is a cost and time-effective way to discover new treatments. Swedish registers are a unique tool to detect medication candidates for repurposing. The Swedish Dementia Registry (SveDem) has \>100000 patients and ca. 144000 measures of cognition over time (measured with the Mini-Mental State Examination-MMSE), making it perfect to examine whether certain medications are associated with less cognitive decline in patients with dementia. Cholesterol and kidney function affect treatment and cognition and are available for 25000 patients. The investigators propose a study combining traditional cohort studies and newer artificial intelligence (machine learning) techniques to detect medications associated with slower cognitive decline in patients from SveDem. The investigators will test pre-specified hypotheses since the investigators suspect specific medications are better candidates to prevent cognitive decline, but the investigators will also let the machine learning algorithms explore the data to find associations that the investigators do not suspect in advance. Finally, the candidate medications will be tested in animal and cellular models to determine the mechanisms of their effects.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 100000 (actual)
- First submitted
- 4 Apr 2023
- Start date
- 1 Jan 2023
- Primary completion date
- 1 Mar 2025
- Lead sponsor
- Karolinska Institutet
- Diseases
- Alzheimer disease
- NCT number
- NCT05817188
What you commit to
- Study type: Observational
- Participants enrolled: 100000
- From 1 Jan 2023 to the primary completion date, 1 Mar 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Lack of Swedish personal identification number or coordination number.
Who the study is looking for
- All patients with dementia registered in SveDem.
Age in the registry: 40 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Karolinska Institutet Coordinator of this site? Confirm its status | Stockholm | Sweden | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.